24 November 2021 - The agenda for the March 2022 PBAC meeting is now available.

The PBAC is due to consider at least 57 submissions (48 initial, 9 resubmissions) at its first scheduled meeting for 2022. More submissions will be added to the agenda in week 8.

Of the 57 submissions:

• 53 (92%) are for a PBS medicine; 2 (4%) are for a PBS medicinal preparation and 2 (4%) are for a NIP vaccine 
• 18 (32%) are for a new medicine
• 14 (25%) are for an oncology; 8 (14%) are for haematology and just 1 (2%) is for a medicine for cardiovascular medicine

Submissions of note:

• A submission from Novo Nordisk for semaglutide (Wegovy) for obesity. The PBAC has already held a stakeholder meeting in advance of this submission.
• A submission from Roche for a new implant formulation of ranibizumab (Susvimo) for age-related macular denegeration
• Submissions from Novo Nordisk and Pfizer for new medicines for patients with growth hormone deficiency; while one medicine (somapacitan; Sogroya) is for adult-onset; the other somatrogon (Ngenla) is for paediatric-onset.

Four companies each lodged 3 submissions:

• AbbVie
• Amgen
• Chiesi
• Sanofi

More insights in tomorrow's edition.

Read PBS News